基本信息
浏览量:0
职业迁徙
个人简介
Professor Harnett has had a long-standing interest in understanding the mechanism underlying how cancers become resistant to chemotherapy, having studied this for over 20 years in numerous cancers with a special interest in ovarian cancer. His team is studying genes that may be implicated in sensitivity/resistance of ovarian cancer to chemotherapy. Professor Harnett holds a patent in Australia and the USA on therapeutic application of a gene involved in determining sensitivity to chemotherapy in ovarian cancer.
Professor Harnett also conducts clinical research including Phase 1 and 2 clinical trials testing new therapeutic agents or regimens for ovarian cancer (e.g. two international trials of MEK inhibition (MEK162 and pimasertib) in Low Grade Serous Carcinoma). Additionally, with his large and active clinical practice in ovarian cancer, he has assembled a (continually accruing) significant cohort of patients for drug and translational studies, with many having had sequential biopsies at multiple points of disease. As the distinct clinical behaviour and biology of subsets of ovarian cancers becomes more apparent, the clinical observations are being translated into research questions, e.g. is there an underlying genetic basis differentiating the extremes of response to ovarian cancer therapy observed in practice (i.e. extremely good responders vs those refractory to treatment)?
Professor Harnett also conducts clinical research including Phase 1 and 2 clinical trials testing new therapeutic agents or regimens for ovarian cancer (e.g. two international trials of MEK inhibition (MEK162 and pimasertib) in Low Grade Serous Carcinoma). Additionally, with his large and active clinical practice in ovarian cancer, he has assembled a (continually accruing) significant cohort of patients for drug and translational studies, with many having had sequential biopsies at multiple points of disease. As the distinct clinical behaviour and biology of subsets of ovarian cancers becomes more apparent, the clinical observations are being translated into research questions, e.g. is there an underlying genetic basis differentiating the extremes of response to ovarian cancer therapy observed in practice (i.e. extremely good responders vs those refractory to treatment)?
研究兴趣
论文共 135 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
medRxiv (Cold Spring Harbor Laboratory) (2023)
Shweta Srinivasa, Michelle Bowman, Leanna Titterton,Paul Harnett,Alison Brand,Judy Kirk,Abiramy Ragunathan
The Australian & New Zealand journal of obstetrics & gynaecologyno. 2 (2023): 241-246
Asia-Pacific Journal of Clinical Oncology (2023)
引用1浏览0引用
1
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn